A Proof of Concept Study to Evaluate the Safety and Efficacy of UB-421 in Combination With Chidamide for Reduction of HIV Reservoir as Compared to UB-421 Alone in ART Stabilized HIV-1 Patients Who Undergo ART Interruption
Latest Information Update: 12 May 2023
At a glance
- Drugs Semzuvolimab (Primary) ; Tucidinostat (Primary)
- Indications HIV-1 infections
- Focus Proof of concept; Therapeutic Use
- Sponsors UBP Greater China (Shanghai) Co., Ltd
- 09 May 2023 Planned End Date changed from 1 Dec 2026 to 1 Dec 2027.
- 09 May 2023 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2026.
- 09 May 2023 Planned initiation date changed from 1 Mar 2023 to 1 Mar 2024.